Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Aquinox Pharmaceuticals
company
About
Aquinox Pharmaceuticals develops and commercializes small molecule therapeutics for the treatment of cancer and inflammatory diseases.
- 11 - 50
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $14.50M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 2004
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Aquinox Pharmaceuticals Inc., a pharmaceutical company, engages in discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer and inflammatory disease. It offers AQX-MN100, a drug used to treat cancer and inflammatory disease, as well as SH2-containing inositol 5'-phosphatase inhibition program for blood cell recovery. The company was founded in 2004 and is based in Vancouver, Canada.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$32.50M
Aquinox Pharmaceuticals has raised a total of
$32.50M
in funding over 2 rounds. Their latest funding was raised on
Apr 3, 2013 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 3, 2013 | Series C | $18M | 1 | — | — | Detail |
| Jun 12, 2007 | Series A | $14.50M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Aquinox Pharmaceuticals is funded by 2 investors.
Inbio Ventures
and BC Advantage Funds
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Inbio Ventures
|
— | Series C |
BC Advantage Funds
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
